Загрузка...
Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
BACKGROUND: Anti-CD19 CAR T cell therapy has demonstrated high response rates in patients with relapsed or refractory (r/r) B cell malignancies but is associated with significant toxicity. Cytokine release syndrome (CRS) is the most significant complication associated with CAR T cell therapy, and it...
Сохранить в:
| Опубликовано в: : | J Hematol Oncol |
|---|---|
| Главные авторы: | , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BioMed Central
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5833070/ https://ncbi.nlm.nih.gov/pubmed/29499750 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-018-0571-y |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|